Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?

Abstract

We have studied the effects of add-on spironolactone treatment (100 mg/day) in 11 patients with idiopathic membranous nephropathy (IMN) and > 3 gm proteinuria/day despite angiotensin converting enzyme (ACE) inhibitor therapy titrated to a systolic/diastolic blood pressure < 120/80 mmHg. Blood pressure, 24-hour urinary protein excretion, and creatinine… (More)

Topics

3 Figures and Tables

Cite this paper

@inproceedings{Cravedi2010SpironolactonePF, title={Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?}, author={Paolo Cravedi and Varusca Brusegan and Piero Ruggenenti and Ruth C. Campbell and Giuseppe Remuzzi}, booktitle={Pharmaceuticals}, year={2010} }